Physician profile
Rajul Malik
NPI 1376517607
$3,123.42
in general payments reported to CMS, 2019-2025
27 companies · $42.58 in 2025
The $42.58 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,337 · 2020: $778 · 2021: $965 · 2025: $42.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $42.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $42.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $689.27 | 2019-2021 | |
| Glaxosmithkline, LLC. | $543.97 | 2019-2021 | |
| Novo Nordisk INC | $405.76 | 2019-2021 | |
| Amgen INC. | $212.68 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $210.96 | 2019-2021 | |
| Astellas Pharma US INC | $189.42 | 2019 | |
| Merck Sharp & Dohme LLC | $157.96 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $104.31 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $102.47 | 2021 | |
| Abbvie INC. | $93.68 | 2019-2025 | |
| Amarin Pharma, INC. | $50.56 | 2019-2021 | |
| Esperion Therapeutics, INC. | $48.09 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $46.97 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $42.41 | 2019 | |
| Stryker Corporation | $33.99 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $24.32 | 2019-2021 | |
| Eisai INC. | $23.16 | 2020 | |
| Xeris Pharmaceuticals, INC. | $22.27 | 2021 | |
| Pfizer INC. | $18.14 | 2019 | |
| Aytu Biopharma, INC. | $16.43 | 2019 | |
| Boston Scientific Corporation | $13.80 | 2021 | |
| Lilly USA, LLC | $13.60 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.94 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.24 | 2019 | |
| Ironwood Pharmaceuticals, INC | $11.61 | 2019 | |
| Neos Therapeutics, LP | $11.57 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $10.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajul Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.